Clinical trials: Cancer Disease Progression
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT07741968
- Testing
- Best Practice, Interview, Supportive Care
- Where
- 11 sites in United States
- Volunteers
- 126 people
- Sponsor
- City of Hope Medical Center
Metastatic Androgen Independent Prostate Cancer
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
- Trial name
- NCT00849290
- Testing
- APC8015F
- Where
- 58 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Dendreon
Cancer
Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival
This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the…
- Trial name
- NCT07731425
- Testing
- FDA explanation for progression-free survival (control), FDA explanation for progression-free survival with overall survival data, NCI explanation for progression-free survival
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- London School of Economics and Political Science
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Metastatic Colorectal Cancer
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
- Trial name
- NCT05281276
- Testing
- chidamide, celecoxib
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Thyroid Cancer
Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model
This study aims to refine the molecular classification of thyroid cancer (TC) using a multi-omics approach. By identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and…
- Trial name
- NCT06969768
- Where
- South Korea
- Volunteers
- 275 people
- Sponsor
- Seoul National University Hospital
Myeloid Malignancies, Lymphoid Malignancies
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
This is a randomized, parallel phase II study to evaluate the rates of progression-free survival and unacceptable toxicity in patients receiving NK cell-enriched donor lymphocyte infusions (DLIs) when administered alone or…
- Trial name
- NK-DCI (NCT02452697)
- Testing
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cristina Gasparetto
Breast Cancer
Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients
One of the recommended treatments for breast cancer is neoadjuvant chemotherapy (NCT), however, only 20% of the patients subject to this therapy present pathologic complete response (pCR).
- Trial name
- KEYMOVE (NCT05976815)
- Testing
- Combined Aerobic and Resistance Exercise
- Where
- Portugal
- Volunteers
- 86 people
- Sponsor
- University Institute of Maia
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Epithelial Ovarian Cancer, Peritoneal Neoplasms
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Background: Birinapant is an experimental cancer treatment drug. It removes certain proteins in cells, which helps to kill the cells.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01681368
- Testing
- Birinapant (TL32711)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Atrophy, Gastric Intestinal Metaplasia
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia.
- Conditions
- Gastric Atrophy, Gastric Intestinal Metaplasia, Dysplasia, Gastric Adenocarcinoma
- Trial name
- NCT06370143
- Testing
- Questionnaire
- Where
- 7 sites in United States
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy
Efficacy and safety of Dalpiciclib combined with third-generation EGFR-TKI in patients with advanced EGFR-mutated non-small cell lung cancer with meningeal metastasis after third-generation TKI and platinum-containing chemotherapy
- Conditions
- Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV, With EGFR Mutations, Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment
- Trial name
- NCT05497076
- Volunteers
- 9 people
- Sponsor
- Fujian Cancer Hospital
Urothelial Carcinoma
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract…
- Trial name
- NCT06120374
- Testing
- Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 178 people
- Sponsor
- Peking University First Hospital
Head and Neck Neoplasms, Neoplasm Metastasis
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
The aim of this study is to determine the activity, to assess the safety and tolerance of BKM120 in adult patients with recurrent or metastatic head and neck cancer progressive under platin and cetuximab-based chemotherapy.
- Conditions
- Head and Neck Neoplasms, Neoplasm Metastasis, Recurrent Disease, Progressive Disease
- Trial name
- PIK-ORL (NCT01737450)
- Testing
- BKM120
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Ischemic Stroke, Acute, Tumor Progression
Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer
Explore with active cancer patients with acute ischemic stroke in the human body characteristic microorganism disorder to clinical prognosis of the predictive value of the secondary objective: to observe with active cancer…
- Trial name
- NCT05553990
- Testing
- intestinal flora disturbance
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Prostate Cancer
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
This is a Phase II study of the investigational drug opaganib. Patients with metastatic castration resistant prostate cancer (mCRPC) who have experienced disease progression while receiving abiraterone or enzalutamide will…
- Trial name
- NCT04207255
- Testing
- Opaganib, Abiraterone, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Medical University of South Carolina
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.